Alexion Receives 2001 Biotechnology Achievement Award

Apr 05, 2001, 01:00 ET from Alexion Pharmaceuticals, Inc.

    CHESHIRE, Conn., April 5 /PRNewswire/ --
 Alexion Pharmaceuticals, Inc. (Nasdaq:   ALXN) is pleased to announce that it
 has been awarded the 2001 Biotechnology Achievement Award for Applied
 Biotechnology from the Biotechnology Study Center at the New York University
 School of Medicine.  At an awards ceremony last night, Alexion scientists were
 honored for their work relating to the role of complement in cardiovascular
 and autoimmune disorders.
     "I am proud to accept this award on behalf of all of the employees at
 Alexion," said Dr. Leonard Bell, President and Chief Executive Officer of
 Alexion Pharmaceuticals.  "All of us at Alexion are extremely proud to have
 the opportunity to progress the work pioneered by renowned NYU researchers.
 It is their scientific foundation that allows us to develop compounds for the
 potential treatment of serious cardiovascular and autoimmune disorders."
     The awards sponsored by the Biotechnology Study Center and The Severo
 Ochoa/Lewis Thomas Societies of NYU School of Medicine, honor scientific
 contributions that, in part, relate to research conducted by faculty members
 of the NYU School of Medicine.  Alexion's work relates to research carried out
 in the 1960's by Lewis Thomas (Dean and Chairman of Medicine at NYU) and on
 C5a in the mid-1970's by Ira Goldstein (associate professor at NYU and later
 Chairman of Medicine at Mt. Sinai).
     Alexion is engaged in the discovery and development of therapeutic
 products aimed at treating patients with a wide array of severe disease
 states, including cardiovascular and autoimmune disorders, inflammation and
 cancer.  Alexion's two lead product candidates are currently in eight clinical
 development programs.  Alexion is developing its antibody fragment,
 pexelizumab, in collaboration with Procter & Gamble, and has completed a Phase
 IIb study in patients undergoing cardiopulmonary bypass, and together the
 firms are currently conducting two large Phase II studies with pexelizumab in
 acute myocardial infarction patients.  Alexion's other lead product candidate,
 5G1.1, has recently completed a Phase II trial for the treatment of rheumatoid
 arthritis. 5G1.1 is also in a Phase II trial for the treatment of membranous
 nephritis and in Phase Ib pilot studies for the treatment of psoriasis,
 dermatomyositis, and pemphigoid.  Additionally, through the creation of its
 wholly owned subsidiary, Alexion Antibody Technologies, Inc., Alexion is
 engaged in discovering and developing a portfolio of additional antibody
 therapeutics targeting severe unmet medical needs.  This press release and
 further information about Alexion Pharmaceuticals, Inc. can be found on the
 World Wide Web at: http://www.AlexionPharm.com.
 
     This news release contains forward-looking statements.  Such statements
 are subject to certain factors which may cause Alexion's plans to differ or
 results to vary from those expected including unexpected pre-clinical or
 clinical results, the need for additional research and testing, delays in
 manufacturing, access to capital and funding, delays and adverse changes in
 development of commercial relationships and a variety of risks set forth from
 time to time in Alexion's filings with the Securities and Exchange Commission,
 including but not limited to the risks discussed in Alexion's Annual Report on
 Form 10-K for the year ended July 31, 2000.  Except in special circumstances
 in which a duty to update arises when prior disclosure becomes materially
 misleading in light of subsequent events, Alexion does not intend to update
 any of these forward-looking statements to reflect events or circumstances
 after the date hereof or to reflect the occurrence of unanticipated events.
 
     CONTACTS:
     Alexion Pharmaceuticals, Inc.
     Leonard Bell, M.D.
     President & CEO
     203-272-2596
 
     Noonan/Russo Communications, Inc.
     Ernie Knewitz (Media)
     212-696-4455, ext. 204
 
     Nexus Communications
     Rhonda Chiger (Investor)
     917-322-2569
 
 

SOURCE Alexion Pharmaceuticals, Inc.
    CHESHIRE, Conn., April 5 /PRNewswire/ --
 Alexion Pharmaceuticals, Inc. (Nasdaq:   ALXN) is pleased to announce that it
 has been awarded the 2001 Biotechnology Achievement Award for Applied
 Biotechnology from the Biotechnology Study Center at the New York University
 School of Medicine.  At an awards ceremony last night, Alexion scientists were
 honored for their work relating to the role of complement in cardiovascular
 and autoimmune disorders.
     "I am proud to accept this award on behalf of all of the employees at
 Alexion," said Dr. Leonard Bell, President and Chief Executive Officer of
 Alexion Pharmaceuticals.  "All of us at Alexion are extremely proud to have
 the opportunity to progress the work pioneered by renowned NYU researchers.
 It is their scientific foundation that allows us to develop compounds for the
 potential treatment of serious cardiovascular and autoimmune disorders."
     The awards sponsored by the Biotechnology Study Center and The Severo
 Ochoa/Lewis Thomas Societies of NYU School of Medicine, honor scientific
 contributions that, in part, relate to research conducted by faculty members
 of the NYU School of Medicine.  Alexion's work relates to research carried out
 in the 1960's by Lewis Thomas (Dean and Chairman of Medicine at NYU) and on
 C5a in the mid-1970's by Ira Goldstein (associate professor at NYU and later
 Chairman of Medicine at Mt. Sinai).
     Alexion is engaged in the discovery and development of therapeutic
 products aimed at treating patients with a wide array of severe disease
 states, including cardiovascular and autoimmune disorders, inflammation and
 cancer.  Alexion's two lead product candidates are currently in eight clinical
 development programs.  Alexion is developing its antibody fragment,
 pexelizumab, in collaboration with Procter & Gamble, and has completed a Phase
 IIb study in patients undergoing cardiopulmonary bypass, and together the
 firms are currently conducting two large Phase II studies with pexelizumab in
 acute myocardial infarction patients.  Alexion's other lead product candidate,
 5G1.1, has recently completed a Phase II trial for the treatment of rheumatoid
 arthritis. 5G1.1 is also in a Phase II trial for the treatment of membranous
 nephritis and in Phase Ib pilot studies for the treatment of psoriasis,
 dermatomyositis, and pemphigoid.  Additionally, through the creation of its
 wholly owned subsidiary, Alexion Antibody Technologies, Inc., Alexion is
 engaged in discovering and developing a portfolio of additional antibody
 therapeutics targeting severe unmet medical needs.  This press release and
 further information about Alexion Pharmaceuticals, Inc. can be found on the
 World Wide Web at: http://www.AlexionPharm.com.
 
     This news release contains forward-looking statements.  Such statements
 are subject to certain factors which may cause Alexion's plans to differ or
 results to vary from those expected including unexpected pre-clinical or
 clinical results, the need for additional research and testing, delays in
 manufacturing, access to capital and funding, delays and adverse changes in
 development of commercial relationships and a variety of risks set forth from
 time to time in Alexion's filings with the Securities and Exchange Commission,
 including but not limited to the risks discussed in Alexion's Annual Report on
 Form 10-K for the year ended July 31, 2000.  Except in special circumstances
 in which a duty to update arises when prior disclosure becomes materially
 misleading in light of subsequent events, Alexion does not intend to update
 any of these forward-looking statements to reflect events or circumstances
 after the date hereof or to reflect the occurrence of unanticipated events.
 
     CONTACTS:
     Alexion Pharmaceuticals, Inc.
     Leonard Bell, M.D.
     President & CEO
     203-272-2596
 
     Noonan/Russo Communications, Inc.
     Ernie Knewitz (Media)
     212-696-4455, ext. 204
 
     Nexus Communications
     Rhonda Chiger (Investor)
     917-322-2569
 
 SOURCE  Alexion Pharmaceuticals, Inc.